4D Molecular Therapeutics Inc (FDMT)
7.99
-0.42
(-4.99%)
USD |
NASDAQ |
Nov 21, 16:00
7.975
-0.02
(-0.19%)
After-Hours: 20:00
4D Molecular Therapeutics Enterprise Value: -132.53M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | -132.53M |
| November 20, 2024 | -113.12M |
| November 19, 2024 | -101.10M |
| November 18, 2024 | -117.28M |
| November 15, 2024 | -93.70M |
| November 14, 2024 | -131.15M |
| November 13, 2024 | -145.48M |
| November 12, 2024 | -138.08M |
| November 11, 2024 | -82.28M |
| November 08, 2024 | -79.68M |
| November 07, 2024 | -71.36M |
| November 06, 2024 | -67.72M |
| November 05, 2024 | -65.64M |
| November 04, 2024 | -76.82M |
| November 01, 2024 | -80.98M |
| October 31, 2024 | -85.40M |
| October 30, 2024 | -71.88M |
| October 29, 2024 | -75.52M |
| October 28, 2024 | -56.28M |
| October 25, 2024 | -78.12M |
| October 24, 2024 | -75.00M |
| October 23, 2024 | -59.40M |
| October 22, 2024 | -72.40M |
| October 21, 2024 | -55.76M |
| October 18, 2024 | -58.36M |
| Date | Value |
|---|---|
| October 17, 2024 | -62.52M |
| October 16, 2024 | -51.60M |
| October 15, 2024 | -39.64M |
| October 14, 2024 | -32.36M |
| October 11, 2024 | -25.08M |
| October 10, 2024 | -47.96M |
| October 09, 2024 | -33.92M |
| October 08, 2024 | -14.16M |
| October 07, 2024 | -20.40M |
| October 04, 2024 | 16.51M |
| October 03, 2024 | 35.75M |
| October 02, 2024 | 32.11M |
| October 01, 2024 | 39.39M |
| September 30, 2024 | 60.19M |
| September 27, 2024 | 20.88M |
| September 26, 2024 | 27.64M |
| September 25, 2024 | 44.27M |
| September 24, 2024 | 55.18M |
| September 23, 2024 | 61.42M |
| September 20, 2024 | 76.49M |
| September 19, 2024 | 159.64M |
| September 18, 2024 | 332.18M |
| September 17, 2024 | 297.88M |
| September 16, 2024 | 314.51M |
| September 13, 2024 | 302.56M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-145.48M
Minimum
Nov 13 2024
1.497B
Maximum
Mar 27 2024
440.30M
Average
444.77M
Median
Enterprise Value Benchmarks
| Regeneron Pharmaceuticals Inc | 74.00B |
| Ocular Therapeutix Inc | 980.09M |
| NovaBay Pharmaceuticals Inc | 2.798M |
| Palatin Technologies Inc | 15.96M |
| iBio Inc | 12.31M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -43.84M |
| Revenue (Quarterly) | 0.003M |
| Total Expenses (Quarterly) | 51.14M |
| EPS Diluted (Quarterly) | -0.79 |
| Profit Margin (Quarterly) | -1.46M% |
| Earnings Yield | -35.67% |
| Normalized Earnings Yield | -35.67 |